EMA Authorised: Sugammadex Amomed (sugammadex sodium) — AOP Orphan Pharmaceuticals GmbH

View source ↗

Summary

The European Medicines Agency authorised Sugammadex Amomed (sugammadex sodium) for reversing neuromuscular blockade during anesthesia, under a new marketing aut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromuscular Blockade Due to Anesthesia

Drugs mentioned

• Sugammadex Amomed (sugammadex sodium)

Snippet

Status: Authorised. Therapeutic area: Neuromuscular Blockade. MAH: AOP Orphan Pharmaceuticals GmbH. Decision date: 02/02/2026